Home > Insider Trading > Filing (0001415889-25-001342)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1786205	Arcellx Inc.	ACLX	Biological Products, (No Disgnostic Substances) (2836)	472855917

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1789632	Christopher Heery	C/O Arcellx, Inc. 800 Bridge Parkway Redwood City CA 94065	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-01-02	13,021	$0.00	22,299	No	4	M	Direct
Common Stock	Disposition	2025-01-03	2,975	$79.55	35,843	No	4	S	Direct
Common Stock	Disposition	2025-01-06	2,975	$77.17	32,868	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2025-01-02	13,021	$0.00	13,021	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
26,042			No	4	M	Direct

Footnotes

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Vesting of these RSUs previously reported in the Form 4 filed January 6, 2025.
Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Amendment filed to report the correct number of shares sold to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units reported in the Form 4 filed on January 6, 2025.
The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices that were not available from the broker at the time of filing. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 2, 2024.